Q-omics provides the consensus-scored MAMSTR profile across patient tissues and cancer cell-line models. MAMSTR expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MAMSTR is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, MAMSTR RNA expression shows 17,543 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, LIHC, and TGCT as cancer lineages where MAMSTR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAMSTR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAMSTR survival associations across molecular data types. MAMSTR RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAMSTR RNA expression–survival associations across cancer types. High MAMSTR expression shows unfavorable associations in BLCA, LIHC, KIRP and ACC, but favorable associations in UVM and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MAMSTR RNA expression.
This table summarizes MAMSTR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MAMSTR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAMSTR shows lower tumor expression in UCEC and KIRC and higher tumor expression in LIHC, LUSC, CHOL and COAD. The LIHC box plot shows higher MAMSTR RNA expression in tumor versus normal tissue (log2 FC = +0.903, t-test p < 0.001).
This table shows molecular features associated with MAMSTR in patient tissues and cancer cell lines. In patient samples, MAMSTR shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MAMSTR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
